Exagen INC Schedule 13G passive stakes

Parian Ultreia LP has filed a Schedule 13G, reporting beneficial ownership of 1,292,000 shares, representing 5.3% of Exagen Inc.'s outstanding class of securities.

Jorey Chernett has filed a Schedule 13G reporting beneficial ownership of 2,413,901 shares, representing a 9.9% stake in Exagen Inc.

RTW Investments and Dr. Roderick Wong have reduced their beneficial ownership in Exagen Inc. to 4.9% of common stock, as reported in their latest Schedule 13G amendment.

NMSIC Co-Investment Fund, L.P. and its general partner, Sun Mountain Capital Partners, L.L.C., reported a 6.04% beneficial ownership stake in Exagen Inc. as of December 31, 2025.

Jorey Chernett has reported beneficial ownership of 5.4% of EXAGEN INC.'s common stock, totaling 1,231,438 shares, as of January 30, 2026.

Laurence W. Lytton reported a 1.0% beneficial ownership stake in Exagen Inc., holding 216,840 shares of common stock as of June 30, 2025.

RTW Investments, LP and Roderick Wong, M.D. reported a 7.7% passive ownership stake in Exagen Inc., holding 1,696,866 common shares as of June 30, 2025.

Cowen Financial Products LLC has filed an amended Schedule 13G, reporting a 5% beneficial ownership stake in Exagen Inc. as of March 31, 2025.

NMSIC Co-Investment Fund, L.P. and Sun Mountain Capital Partners, L.L.C. have reported a combined beneficial ownership of 9.83% in Exagen Inc., totaling 1,758,958 shares of common stock.

NMSIC Co-Investment Fund, L.P. and its general partner, Sun Mountain Capital Partners LLC, have reported a beneficial ownership of 11.96% in Exagen Inc., holding 2,108,958 shares as of December 31, 2024.